Frequency of P16INK4a and P14ARF genes methylation and its impact on bladder cancer cases in north Indian population

Disease Markers

Volumn 28, Issue 6, 2010, Pages 361-368

  Hosseini, Seyed Ali ^a,b   Sobti, Ranbir Chander ^a   Malekzadeh, Kianoosh ^a   Singh, Shrawan Kumar ^c   Joshi, Kusum ^c  

^a PANJAB UNIVERSITY   (India)

^b NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^c Post Graduate of Medical Education and Research   (Iran)

Author keywords

Bladder cancer; Methylation; P14Arf; P16Ink4A; Tumour suppressor gene

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA;

ADULT; AGED; ARTICLE; BLADDER; BLADDER TUMOR; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENETICS; HUMAN; INDIA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P14ARF; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 78149478383     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2010-0716     Document Type: Article

References (55)

1. U.S. National Cancer Institute, bladder cancer. Available at:http://www.cancer.gov/bladder accessed November1, 2008.
2. M. Vaish, A. Mandhani, R.D. Mittal and B. Mittal, Microsatellite instability as prognostic marker in bladder tumors: a clinical significance, BMC Urology 5 (2005), 2471-2490.
3. D. Matthew, Galsky andW. Robert, Bladder Cancer, Text book of Kidney and Urinary Tract, 8th Edition. Wolters Kluwer:Lippincott Williams&Wilkins Co., 2007, 777-785.
4. M.P. Zeegers, R.A. Goldbohm and P.A. van den Brant, A prospective study on active and environmental tobacco smoking and bladder cancer risk, Cancer Causes Control 13(1) (2002), 83-86.
5. http://www.oncologyradiation.com/, radiation-therapy-bladder-cancer.
6. D. Sidransky, P. Frost, A. von Eschenbach, R. Oyasu, A.C. Preisinger and B. Vogelstein, Clonal origin of bladder cancer, N Engl J Med 326 (1992), 737-740.
7. L. Mao, D.J. Lee, M.S. Tockman, Y.S. Erozan, F. Askin and D. Sidransky, Microsatellite alterations as clonal markers for the detection of human cancers, Proc Natl Acad Sci USA 91 (1994), 9871-9875.
8. T. Habuchi, R. Takahashi, H. Yamada, Y. Kakehi, T. Sugiyama and O. Yoshida, Metachronous multifocal development of urothelial cancers by intraluminal seeding, Lancet 342 (1993), 1087-1088.
9. I.H.Wong, Y.M. Lo and P.J. Johnson, Epigenetic tumor markers in plasma and serum: biology and applications to molecular diagnosis and disease monitoring, Ann N Y Acad Sci 945 (2001), 36-50.
10. S.B. Baylin and J.G. Herman, DNA hypermethylation in tumorigenesis:epigenetics joins genetics, Trends Genet, 16 (2000), 168-174.
11. P.A. Jones and S.B. Baylin, The fundamental role of epigenetic events in cancer, Nat Rev Genet 3 (2002), 415-428.
12. M. Partha, Das and Rakesh Singal, DNA Methylation and Cancer, J Clin Oncol 22 (2004), 4632-4642. by American Society of Clinical Oncology.
13. P.A. Jones and P.W. Laird, Cancer epigenetics comes of age, Nat Genet 21 (1999), 163-167.
14. M. Esteller, CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future, Oncogene 21 (2002), 5427-5440.
15. M. Esteller, Relevance of DNA methylation in the management of cancer, Lancet Oncol 4 (2003), 351-358.
16. A. Patel, J.D. Groopman and A. Umar, DNA methylation as a cancerspecific biomarker: from molecules to populations, Ann N Y Acad Sci 983 (2003), 286-297.
17. S.E. Cottrell and P.W. Laird, Sensitive detection of DNA methylation, Ann N Y Acad Sci 983 (2003), 120-130.
18. P.W. Laird, The power and the promise of DNA methylation markers, Nat Rev Cancer 3 (2003), 253-266.
19. J. Hayslip and A. Montero, Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review, Molecular Cancer 5 (2006), 44-48.
20. J.C. Richard, P.W. Laird and R.H. Datar, Promoter Hypermethylation. A New Therapeutic Target Emerges in Urothelial Cancer, Journal of Clinical Oncology 23(13) (2005), 2879-2881.
21. M.W. Chan, L.W. Chan and N.L. Tang, Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients, Int J Cancer 104 (2003), 611-616.
22. L.L. Chang, W.T. Yeh and S.Y. Yang, Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer, JUrol 170 (2003), 595-600.
23. Y. Horikawa, K. Sugano and M. Shigyo, Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ, J Urol 169 (2003), 1541-1545.
24. G. Dominguez, J. Silva and J.M. Garcia, Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors, Mutat Res 530 (2003), 9-17.
25. C. Bernal, F. Aguayo, C. Villarroel, M. Vargas, I. Díaz, F.J. Ossandon, E. Santibáñez, M. Palma, E. Aravena, C. Barrientos and A.H. Corvalan, Reprimo as a potential biomarker for early detection in gastric cancer, Clin Cancer Res 14(19) (2008), 6264-6269.
26. G. Sharma, S. Mirza, C.P. Prasad, A. Srivastava, S.D. Gupta and R. Ralhan, Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients, Life Science 80 (2007), 1873-1881.
27. C.S. Chim, Y.L. Kwong and R. Liang, Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach, Clin Lymphoma Myeloma 8(6) (2008), 331-339.
28. R.T. Williams and C.J. Sherr, The INK4-ARF (CDKN2A/B) Locus in Hematopoiesis and BCR-ABL-induced Leukemias, Cold Spring Harb Symp Quant Biol. 2008 Nov 26. [Epub ahead of print].
29. S.J. Gallagher, J.F. Thompson, J. Indsto, L.L. Scurr, M. Lett, B.F. Gao, R. Dunleavey, G.J. Mann, R.F. Kefford and H. Rizos, p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors, Neoplasia 10(11) (2008), 1231-1239.
30. C. Fan, L. He, A. Kapoor, A. Gillis, A.P. Rybak, J.C. Cutz and D. Tang, Bmi1 promotes prostate tumorigenesis via inhibiting p16(INK4A) and p14(ARF) expression, Biochim Biophys Acta 1782(11) (2008), 642-648.
31. J.G. Herman, J.R. Graff, S. Myöhänen, B.D. Nelkin and S.B. Baylin, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands, PNAS 93 (1996), 9821-9826.
32. E.P. Xing, Y. Nie, Y. Song, G.Y. Yang, Y.C. Cai, L.D. Wang and C.S. Yang, Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma, Clin Cancer Res 5(10) (1999), 2704-2713.
33. J.F. Viallard, F. Lacombe, F. Belloc, J.L. Pellegrin and J. Reiffers, Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology, Cancer Radiother 5(2) (2001), 109-129.
34. K. Yamashita, S. Upadhyay and M. Osada, Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma, Cancer Cell 2 (2002), 485-495.
35. C. Jeronimo, R. Henrique and M.O. Hoque, A quantitative promoter methylation profile of prostate cancer, Clin Cancer Res 10 (2004), 8472-8478.
36. D.R. Yates, I. Rehman, M.F. Abbod, M. Meuth, S.S. Cross, D.A. Linkens, F.C. Hamdy and J.W.F. Catto, Promoter Hypermethylation Identifies Progression Risk in Bladder, Cancer-Clinical Cancer Research 13 (2007), 2046.
37. L. Shen, H. Kantarjian, Y. Guo, E. Lin, J. Shan, X. Huang, D. Berry, S. Ahmed, W. Zhu, Sh. Pierce, Y. Kondo, Y. Oki, J.Jelinek, H. Saba, E. Estey and J.J. Issa, DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes, Journal of Clinical Oncology 28(4) (2010), 605-613.
38. L. Mao, M.P. Schoenberg, M. Scicchitano, Y.S. Erozan, A. Merlo and D. Schwab, Molecular detection of primary bladder cancer by microsatellite analysis, Science 271 (1996), 659-662.
39. G. Steiner, M.P. Schoenberg, J.F. Linn, L. Mao and D. Sidransky, Detection of bladder cancer recurrence by microsatellite analysis of urine, Nat Med 3 (1997), 621-624.
40. P. Cairns, T.J. Polascik, Y. Eby, K. Tokino, J. Califano and A. Merlo, Frequency of homozygous deletion at p16/CDKN2 in primary human tumours, Nat Genet 11 (1995),210-212.
41. M. Esteller, M.F. Fraga, M.F. Paz, E. Campo, D. Colomer, F.J. Novo, M.J. Calasanz, O. Galm, M. Guo, J. Benitez and J.G. Herman, Cancer epigenetics and methylation, Science 297 (2002), 1807-1808.
42. M.D. Shahbazian and H.Y. Zoghbi, Rett syndrome and MeCP2: linking epigenetics and neuronal function, Am J Hum Genet 71 (2002), 1259-1272.
43. N. Lopatina, J.F. Haskell, L.G. Andrews, J.C. Poole, S.Saldanha and T.O. Tollefsbol, Differential maintenance and de novo methylating activity by three DNA methyltransferases in aging and immortalized fibroblasts, J Cell Biochem 84 (2002), 324-334.
44. B.C. Christensen, J.J. Godleski, C.J. Marsit, E.A. Houseman and C.Y. Lopez-Fagundo. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma, Carcinogenesis 29 (2008), 1555-1559.
45. C.J. Marsit, E.A. Houseman, A.R. Schned, M.R. Karagas and K.T. Kelsey, Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer, Carcinogenesis 28 (2007), 1745-1751.
46. C.J. Marsit, M.D. McClean, C.S. Furniss and K.T. Kelsey, Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma, Int J Cancer 119 (2006), 1761-1766.
47. S. Toyooka, R. Maruyama, K.O.Toyooka, D. McLerran and Z. Feng, Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer, Int J Cancer 103 (2003), 153-160.
48. C.M. Lyon, D.M. Klinge, K.C. Liechty, F.D. Gentry and T.H. March, Radiation-induced lung adenocarcinoma is associated with increased frequency of genes inactivated by promoter hypermethylation, Radiat Res 168 (2007), 409-414.
49. B.C. Christensen, E.A. Houseman, J.J. Godleski, C.J. Marsit, J.L. Longacker, Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome, Cancer Res, 2008.
50. D.H. Kim, H.H. Nelson, J.K. Wiencke, D.C. Christiani, J.C. Wain, E.J. Mark and K.T. Kelsey, Promoter hypermethylation of DAP-kinase: association with advanced stage in non-small cell lung cancer, Oncogene, 2001, in press.
51. E.M. Wolff, G. Liang, C.C. Cortez, Y.C. Tsai, J.E. Castelao, V.K. Cortessis, D.D. Tsao-Wei, S. Groshen and P.A. Jones, RUNX3 Methylation Reveals that Bladder Tumors Are Older in Patients with a History of Smoking, Cancer Research 68 (2008), 6208-6214.
52. C. Ch. Brock, E.A. Houseman, J.M. Carmen, Sh. Zheng, R.W. Margaret, J.L. Wiemels, H.H. Nelson, M.R. Karagas, J.F. Padbury, R. Bueno, D.J. Sugarbaker, R. Yeh, J.K. Wiencke and K.T. Kelsey, Aging and Environmental Exposures Alter Tissue-Specific DNA Methylation Dependent upon CpG Island Context, PLoS Genet 5(8) (2009), e1000602.
53. Y.Wei, S.Wu, Y.Ma and H. Lee, Respiratory Function Decline and DNA Mutation in Mitochondria, Oxidative Stress and Altered Gene Expression during Aging, Chang Gung Med J 32 (2009), 113-132.
54. W.C. Copeland, J.T.Wachsman, F.M. Johnson and J.S. Penta, Mitochondrial DNA alterations in cancer, Cancer Invest 20 (2002), 557-569.
55. C. Xie, A. Naito, T. Mizumachi, T.T. Evans, M.G. Douglas, C.A. Cooney, C. Fan and M. Higuchi, Mitochondrial regulation of Cancer Associated Nuclear DNA Methylation, Biochem Biophys Res Commun 364(3) (2007), 656-661.